Lorigerlimab

DRUG9 trials

Conditions

Advanced CancerAdvanced Solid TumorAndrogen-Independent Prostatic CancerAndrogen-Independent Prostatic NeoplasmsAndrogen-Insensitive Prostatic CanceAndrogen-Resistant Prostatic CancerCastration-Resistant Prostatic CancerCervical Cancer

Phase 1

MGD019 DART® Protein in Unresectable/Metastatic Cancer

CompletedNCT03761017

MacroGenicsAdvanced Cancer, Colorectal Cancer, Cutaneous Melanoma +3

Start: 2018-12-12End: 2025-01-27Updated: 2025-03-06

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

CompletedNCT05293496

MacroGenicsAdvanced Solid Tumor, Castration-Resistant Prostatic Cancer, Epithelial Ovarian Cancer +4

Start: 2022-04-19End: 2025-08-26Updated: 2025-10-14

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

WithdrawnNCT07137390

M.D. Anderson Cancer CenterColorectal Cancer

Start: 2025-09-03End: 2026-01-22Updated: 2026-03-11

Phase 2

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

RecruitingNCT05475171

M.D. Anderson Cancer CenterCervical Cancer, Metastatic Cancer

Start: 2022-12-13End: 2028-06-30Target: 60Updated: 2026-09-17

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT05848011

MacroGenicsAndrogen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Androgen-Insensitive Prostatic Cance +6

Start: 2023-09-28End: 2026-03-16Updated: 2026-05-22

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

RecruitingNCT06730347

MacroGenicsClear Cell Adenocarcinoma of Cervix, Clear Cell Adenocarcinoma of Fallopian Tube, Clear Cell Adenocarcinoma of Ovary +8

Start: 2025-05-01End: 2027-12-01Target: 80Updated: 2026-06-02

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

RecruitingNCT07071961

M.D. Anderson Cancer CenterColorectal Cancer, High Risk Patients, Regorafenib

Start: 2026-02-11End: 2029-05-01Target: 16Updated: 2026-08-27

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

WithdrawnNCT07223567

M.D. Anderson Cancer CenterRectal Cancer, Rectal Cancer Recurrent

Start: 2025-10-27End: 2026-01-22Updated: 2026-02-25

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Not yet recruitingNCT07565155

Peter Hosein, MDHomologous Recombination Deficiency, Pancreatic Adenocarcinoma

Start: 2026-06-01End: 2031-06-01Target: 40Updated: 2026-05-04

Cancer Research2026-04-17

Triage of advanced cervical cancer through immunotherapy induction (TRACTION).

Journal of Clinical Oncology2024-06-01

LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2024-01-29

Lorigerlimab, a bispecific PD-1×CTLA-4 DART molecule in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase 1 expansion (exp) cohort.

Journal of Clinical Oncology2023-02-2011 citations

757 A phase 1/1b dose escalation and cohort expansion study of MGC018 in combination with lorigerlimab in patients with advanced solid tumors (AST)

Regular and Young Investigator Award Abstracts2022-11-015 citations

Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule.

2020-12-2242 citations

A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

Journal of Clinical Oncology2019-05-202 citations

Lorigerlimab

Sponsors

Conditions

Phase 1

Phase 2

Related Papers